[1] O’Brien K D. Pathogenesis of calcific aortic valve disease:a disease process comes of age (and a good deal more) [J]. ArteriosclerThrombVasc Biol,2006,26(8):1721-1728.
[2] Pibarot P,Dumesnil J G. New concepts in valvularhemodynamics:implications for diagnosis and treatment of aortic stenosis[J]. Can J Cardiol,2007,23(Suppl B):40-47.
[3] Cribier A,Eltchaninoff H,Bash A,et al.Percutaneous transcath—eter implantation of an aortic valve prosthesis for calcific aorticstenosis:first human case description[J].Circulation,2002,106(24):3006-3008.
[4] 潘文志,葛均波. 经导管主动脉瓣置入术2013 年进展回顾[J]. 中国介入心脏病学杂志,2014,22 (1) : 52-54.
[5] 葛均波,周达新,潘文志,等.经皮主动脉瓣植入术一例报道附操作要点[J].中国介入心脏病杂志,2010,18(5):9-12.
[6] Leon M B,Smith C R,Mack M,et al.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery[J].NEngl J Med,2010,363(17):1597-1607.
[7] Smith C R,Leon M B,Mack M J,et al.Transcatheterversus surgical aortic-valve replacement in high-risk patients[J].N Engl J Med,2011,364(23):2187-2198.
[8] Kapadia S R,Tuzcu E M,Makkar R R,et al.Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy[J].Circulation,2014,130(17):1483-1492.
[9] Abdel-Wahab M,Mehilli J,Frerker C,et al. Comparison of balloon-expandable vsself-expandable valves in patients undergoing transcatheter aortic valvereplacement: the CHOICE randomized clinical trial[J]. JAMA,2014,311(15):1503-1514.
[10] Sherif M A,Abdel-Wahab M,Stocker B,et al. Anatomic and procedural predictors ofparavalvular aortic regurgitation after implantation of the Medtronic CoreValvebioprosthesis[J].J Am Coll Cardiol,2010,56(20):1623-1629.
[11] Wong D T,Bertaso A G,Liew G Y,et al. Relationship of aortic annular eccentricityand paravalvular regurgitation post transcatheter aortic valve implantation withCoreValve[J].J Invasive Cardiol,2013,25(4):190-195.
[12] Tuzcu E M,Kapadia S R. Selection of valves for TAVR: is the CHOICE clear?[J].JAMA,2014,311(15):1500-1502.
[13] Cribier A,Eltchaninoff H,Tron C,et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis[J]. J Am Coll Cardiol,2004, 43( 4) : 698-703.
[14] Grube E,Schuler G, Buellesfeld L,et al.Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third -generation self-expanding CoreValveprosthesis:device success and 30-day clinical outcome[J].J Am Coil Cardiol,2007,50(1):69-76.
[15] Lichtenstein S V,Cheung A,Ye J,et al.Transapical transcatheter aortic valve implantation in humans:initial clinical experience[J].Circulation,2006,114(6):591-596.
[16] Fraccaro C,Napodano M,Tarantini G,et al. Expanding the eligibility for transcatheter aortic valve implantation the trans- subclavian retrograde approach using: the III generation CoreValverevalvingsystem[J]. JACC Cardiovasc Interv,2009,2(9) : 828-833.
[17] Lopez Otero D,Munoz Garcia A J,Avanzas P,et al.Axillary approach for transcatheter aortic valve implantation:optimization of the endovascular treatment for the aortic valve stenosis[J]. Rev Esp Cardiol,2011, 64( 2) :121-126.
[18] Bapat V,Khawaja M Z,Attia R,et al. TransaorticTranscatheter Aortic valve implantation using Edwards Sapien valve: a novel approach[J]. Catheter Cardiovasc Interv,2012,79(5) : 733-740.
[19] Mouillet G,Desgranges P,Teiger E. Transcatheter aortic valve implantation when classical access routes are unavailable[J]. Catheter Cardiovasc Interv,2011,78 (7) :1004-1007.
[20] Kapadia S R,Svensson L G,Roselli E,et al. Single center TAVR experience with afocus on the prevention and management of catastrophic complications[J]. CatheterCardiovasc Interv,2014,84(5):834-842.
[21] Motloch L J,Rottlaender D,Reda S,et al. Local versus general anesthesia fortransfemoral aortic valve implantation[J]. Clin Res Cardiol,2012,101(1):45-53.
[22] Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoraltranscatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis[J]. JACC Cardiovasc Interv,2014,7(8):898-904
[23] Nishimura R A,Otto C M,Bonow R O,et al.2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease:executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation. 2014;129(23):2440-2492.
[24] Yousef A,Simard T,Pourdjabbar A,et al. Performance of transcatheter aortic valveimplantation in patients with bicuspid aortic valve: systematic review[J]. Int J Cardiol,2014,176(2):562-564.
[25] Seiffert M, Bader R,Kappert U,et al. Initial German experience with transapicalimplantation of a second-generation transcatheter heart valve for the treatment ofaortic regurgitation[J].JACC Cardiovasc Interv,2014,7(10):1168-1174.
[26] Dvir D, Webb J G,Bleiziffer S,et al. Transcatheter aortic valve implantation in failedbioprosthetic surgical valves[J].JAMA ,2014,312(2):162-170.
[27] Gurvitch R,Wood D A,Tay E L, et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort[J]. Circulation,2010,122(13):1319-1327.
[28] Shannon J,Mussardo M,Latib A,et al. Recognition and management of complications during transcatheter aortic valve implantation [J]. Expert Rev Cardiovasc Ther,2011,9(7):913-926.
[29] Kodali S K,Williams M R,Smith C R,et al. Two-year outcomes after transcatheter orsurgical aortic-valve replacement [J].N Engl J Med,2012,366(18):1686-1695.
[30] Kahlert P,Al-Rashid F,Weber M,et al.Vascular access site complications after percutaneous transfemoral aortic valve implantation [J].Herz,2009,34(5):398-408.
[31] Van Mieghem N M,Nuis R J,Piazza N,et al. Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System: the Rotterdam experience[J]. EuroIntervention,2010,5(6):673-679.
[32] Krishnaswamy A,Parashar A,Agarwal S,et al. Predicting vascular complicationsduring transfemoraltranscatheter aortic valve replacement using computedtomography: a novel area-based index[J].Catheter Cardiovasc Interv2014;84(5):844-851.
[33] Masson J B,Kovac J,Schuler G,et al. Transcatheter aortic valve implantation: review of the nature,management,and avoidance of procedural complications[J].JACC Cardiovasc Interv,2009,2(9) : 811-820.
[34] Tay E L,Gurvitch R,Wijesinghe N,et al.A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation[J].JACC Cardiovasc Interv,2011,4(12):1290-1297.
[35] Onsea K,Agostoni P,Samim M,et al.First-in-man experience with a new embolic deflection device in transcatheter aortic valve interventions[J].Euro Intervention,2012,8(1):51-56.
[36] Athappan G,Gajulapalli R D,Sengodan P,et al.Influence of TAVR strategy andvalve design on stroke after transcatheter aortic valve replacement: a meta-analysisand systematic review of literature[J].J Am Coll Cardiol,2014,63(20):2101-2110.
[37] Amat Santos I J,Rodés Cabau J,Urena M,et al.Incidence,predictivefactors,and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation[J].J Am Coll Cardiol,2012,59(2):178-188.
[38] Alassar A,Roy D,Abdulkareem N,et al. Acute kidney injury after transcatheter aortic valve implanation: incidence,rickfactors,and prognostic effects[J]. Innovations,2012,7(6):389-383.
[39] Kong W Y,Yong G,Irish A. Incidence,risk factors and prognosis of acute kidney injury after transcatheter aortic valve implantation[J]. Nephrology(Carlton) ,2012,17 (5) : 445-451.
[40] Gotzmann M,Hehen T,Germing A,et al. Short-term effects of transcatheter aortic valve implantation on neurohormonalactivation,quality of life and 6-minute walk test in severe and symptomatic aortic stenosis[J]. Heart,2010,96(14):1102-1106.
[41] Leon M B,Smith C R,Mack M,et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery[J]. N Engl J Med,2010,363(17):1597-1607.